ALT Research and Charts

ALT - Altimmune Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-04-03)

Last 4.46	Change ⇓ -0.32 (-6.69%)	Volume 2,004,117
	Open 4.48	High 4.73	Low 4.43

8EMA (Daily) 5.04	40EMA (Daily) 5.84	50EMA (Daily) 6.00	STO (Daily) 9.471	MACD Hist (Daily) -0.205
8EMA (Weekly) 5.695	40EMA (Weekly) 6.78	50EMA (Weekly) 6.86	STO (Weekly) 8.180	MACD Hist (Weekly) -0.490


Company Profile
Altimmune Inc is a United States-based clinical-stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of liver diseases. The firm's product candidates include NasoVAX, HepTcell, ALT-801, T-COVID, and NasoShield. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.